All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1400+ biotech and pharma professionals? Let’s chat. 👍

🦃 FYI the newsletter’s taking a break for American Thanksgiving so the next edition will be on Monday, December 2nd - safe journey to all those traveling this week!❄️

THE GOOD
Approvals & Labels

Shorla Oncology’s oral liquid Gleevec (Novartis, tyrosine kinases inhibitor) formulation lands FDA approval; strawberry anyone?
Small molecule, leukemia, cancer - Read more

THE GOOD
Business Development

Nerviano Medical Sciences buys back NMS-293 (PARP1 inhibitor) rights from Merck KGaA
Small molecule, glioblastoma, cancer - Read more

Boan Biotech licenses Brazil commercial rights of denosumab biosimilars to unnamed partner
Monoclonal antibody, osteoporosis - Read more

THE GOOD
Clinical Trial

Amgen’s MariTide (GLP-1 agonist, GIPR antagonist) touts 20% weight loss on average in Ph2, but lofty analyst expectations weren’t met
GLP-1, obesity - Read more

Axsome Therapeutics isn’t sleeping on AXS-12 (norepinephrine reuptake inhibitor, cortical dopamine modulator) Ph3 narcolepsy win, plans approval
Small molecule, narcolepsy - Read more

Maat Pharma’s MaaT-033 immune system modulatory looks primed for Ph2 after positive Ph1b readout
Fecal microbiotherapy, amyotrophic lateral sclerosis (ALS) - Read more 

IGC Pharma presents additional Ph2 data for IGC-AD1’s (CB1, CB2, GPCR modulator) cognitive benefits in Alzheimer’s disease
Small molecule, Alzheimer’s disease - Read more

PRESENTED BY YOU?
Get the attention of 1400+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Secretome Therapeutics $20.4M equity raise
Cell therapy, heart failure, cardiomyopathy, neonatal cardiac progenitor cells - Read more

Biolevate €6M ($6.3M) Seed raise, AI-enabled platform for therapeutic market access
Market access, therapeutic availability, AI - Read more

Doron Therapeutics $11M Series A, intra-articular biologic drug for treating symptomatic knee osteoarthritis
Biologic, osteoarthritis - Read more

Cradle Bio $73M Series B, AI-driven protein design
Biologics, drug design, generative AI - Read more

35Pharma $53M Series C, pipeline of ligand traps, activin inhibitors for pulmonary hypertension, obesity, cardiometabolic disease
Protein drug, hypertension, obesity - Read more

Eisbach Bio nabs Cancer Prevention and Research Institute of Texas reward, $4.75M, clinical development of EIS-12656 (ALC1 inhibitor)
Small molecule, solid tumor, cancer - Read more

Aviceda Therapeutics files plans for $200M equity raise
Small molecule, eye disease, fibrosis, neurological disorder - Read more 

THE GOOD
Investments

Hovione completes New Jersey, USA and Cork, Ireland expansion projects
CDMO, spraydrying - Read more

THE GOOD
Lawsuits

Guardant Health comes out on top in Natera false advertising suit, awarded $292M by jury
Diagnostics, blood test, liquid biopsy, colorectal cancer - Read more

THE GOOD
Mergers & Acquisitions

Roche buys out cell therapy partner Poseida Therapeutics for $1B
Cell therapy, cancer, allogeneic, gene-editing - Read more

THE GOOD
Partnerships

Arrowhead Pharmaceuticals, Sarepta Therapeutics development and licensing partnership for rare genetic diseases
RNAi, rare disease - Read more

Eisai, National Center of Neurology and Psychiatry research arrangement for apolipoprotein E (APOE) genetic testing in the dementia/Alzheimer’s disease
Genetic testing, dementia, Alzheimer’s disease - Read more

THE GOOD
Politics & Policy

Biden administration considers covering obesity meds (eg. Wegovy, Zepbound) under Medicare/Medicaid
GLP-1, obesity, medicare/medicaid coverage - Read more

THE GOOD
Strategic Plans

Agilent Technologies announced major reorganization of business into three distinct groups
Corporate restructuring - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Soleno Therapeutics diazoxide choline (potassium channel activator) FDA PDUFA date pushed back by three months
Small molecule, Prader-Willi syndrome - Read more

THE BAD
Clinical Trials

Roche’s tiragolumab (anti-TIGIT) misses in lung cancer Ph3
Monoclonal antibody, lung cancer - Read more

Alector’s Alzheimer’s hopeful AL002 (TREM2 targeting) fails in Ph2
Monoclonal antibody, Alzheimer’s disease - Read more

PTC Therapeutics’ utreloxastat (15‐lipoxygenase inhibitor) stumbles in Ph2
Small molecule, amyotrophic lateral sclerosis (ALS) - Read more

THE BAD
Company Shutdowns

Alladapt Immunotherapeutics allergic to survival as biotech shuts down
Small molecule, food allergy - Read more [Paywall]

THE BAD
Layoffs

Alector cuts 17% of staff after Ph2 failure
Monoclonal antibody, Alzheimer’s disease - Read more

Medigene cuts 40% of staff
TCR-guided therapy, cancer - Read more

THE BAD
Politics & Policy

President-elect Trump picks COVID herd immunity fan as next head of NIH
Political appointee, national institute of health - Read more

THE UGLY
Public Health

Investigation into British Columbia, Canada H5N1 (bird flu) infection origin hits a dead end
H5N1 (bird flu), infectious disease - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here